Terns Pharmaceuticals, Inc. EBITDA

EBITDA of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBITDA growth rates and interactive chart. Earnings before interest, tax, depreciation and amortization (EBITDA) is a measure of a company's operating performance. Essentially, it's a way to evaluate a company's performance without having to factor in depreciation, interest expenses (debt), writedowns or other accounting measures and taxes. EBITDA, however, can be misleading because it strips out the cost of capital investments like property, plant, and equipment. To calculate EBITDA, take operating profit (also called EBIT) and add back depreciation and amortization.


Highlights and Quick Summary

  • EBITDA for the quarter ending March 31, 2022 was $-12.9 Million (a -6.03% decrease compared to previous quarter)
  • Year-over-year quarterly EBITDA increased by 20.89%
  • Annual EBITDA for 2021 was $-49.3 Million (a 34.72% increase from previous year)
  • Annual EBITDA for 2020 was $-36.6 Million (a -47.67% decrease from previous year)
  • Annual EBITDA for 2019 was $-70 Million (a 280.65% increase from previous year)
  • Twelve month EBITDA ending March 31, 2022 was $-49.2 Million (a -0.39% decrease compared to previous quarter)
  • Twelve month trailing EBITDA increased by 19.54% year-over-year
Trailing EBITDA for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-49.2 Million $-49.3 Million $-44.2 Million $-41.1 Million
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBITDA of Terns Pharmaceuticals, Inc.

Most recent EBITDAof TERN including historical data for past 10 years.

Interactive Chart of EBITDA of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. EBITDA for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-12.93
2021 $-13.76 $-11.76 $-10.7 $-13.12 $-49.35
2020 $-8.66 $-8.64 $-10.0 $-9.3 $-36.63
2019 $-9.87 $-70.0
2018 $-18.39

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.